NYMOZARFEX
Live / Applied — Third extension granted (statement of use) (as of 03 Mar 2026)
What this means for you
Not registered yet, but its 22 Jan 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98369282
- Mark type
- Stylized text
- Filed
- 22 Jan 2024
- Published for opposition
- 09 Jul 2024
- Attorney of record
- Patrick J. Jennings
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of benign prostatic hyperplasia and prostate cancer
Owner
- Nymox Pharmaceutical Corporation, Nassau, BS
- Nymox Pharmaceutical Corporation, Nassau, BS
Prosecution history
- 04 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Mar 2026 — SOU EXTENSION 3 GRANTED
- 03 Mar 2026 — SOU EXTENSION 3 FILED
- 03 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 28 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Jan 2026 — SOU EXTENSION 2 GRANTED
- 02 Sept 2025 — SOU EXTENSION 2 FILED
- 26 Jan 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 08 Dec 2025 — SOU EXTENSION RECEIVED WITH TEAS PETITION
- 08 Dec 2025 — NOTICE OF REVIVAL - E-MAILED
- 08 Dec 2025 — PETITION TO REVIVE-GRANTED
- 08 Dec 2025 — TEAS PETITION TO REVIVE RECEIVED
- 06 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 06 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 26 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED